NCT05122494: A Phase III Study of the Efficacy and Safety of Hemay022 + Aromatase Inhibitor (AI) in Participants With ER+/HER2+ Advanced or Metastatic Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 3
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with brain and/or leptomeningeal metastases; Patients with a history of HER2 targeting tyrosine kinase inhibitors (e.g. Tukysa/tucatinib, Nerlynx/neratinib, Tykerb/lapatinib); Patients who have received more than 1 line of chemotherapy in the metastatic setting

Comments are closed.

Up ↑